Envoy Medical (NASDAQ:COCH) and Alphatec (NASDAQ:ATEC) Head to Head Analysis

Envoy Medical (NASDAQ:COCH) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Valuation & Earnings

This table compares Envoy Medical and Alphatec”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$240,000.00	206.29	-$23.76 million	($1.01)	-0.64
Alphatec	$764.16 million	1.65	-$143.36 million	($0.82)	-10.00

Envoy Medical has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Envoy Medical has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.

Institutional & Insider Ownership

8.6% of Envoy Medical shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 7.1% of Envoy Medical shares are owned by company insiders. Comparatively, 13.5% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Envoy Medical and Alphatec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-9,875.64%	N/A	-177.92%
Alphatec	-15.93%	-1,183.84%	-15.83%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Envoy Medical and Alphatec, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	1	1	1	0	2.00
Alphatec	1	1	10	0	2.75

Envoy Medical presently has a consensus target price of $2.50, suggesting a potential upside of 288.20%. Alphatec has a consensus target price of $18.58, suggesting a potential upside of 126.54%. Given Envoy Medical’s higher possible upside, equities research analysts plainly believe Envoy Medical is more favorable than Alphatec.

Summary

Alphatec beats Envoy Medical on 8 of the 14 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.